Bookrunners Jefferies and Barclays to assist with sale of common stock
By Devika Patel
Knoxville, Tenn., Sept. 18 – Aratana Therapeutics, Inc. priced a $41.63 million public sale of stock with a $6.24 million greenshoe, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission. The deal was announced Sept. 16.
The company will sell 4.5 million common shares at $9.25 apiece. The price per share is an 8.14% discount to the Sept. 17 closing share price of $10.07.
Jefferies and Barclays are the joint bookrunning managers.
Settlement is expected Sept. 22.
Proceeds will be used for development of therapeutic candidates, expansion of commercial infrastructure and for other general corporate and working capital purposes.
Based in Kansas City, Kan., the development-stage biopharmaceutical company is focused on pet medications.
| Issuer: | Aratana Therapeutics, Inc.
|
| Issue: | Common shares
|
| Amount: | $41,625,000
|
| Greenshoe: | $6,243,750
|
| Shares: | 4.5 million
|
| Price: | $9.25
|
| Warrants: | No
|
| Bookrunners: | Jefferies and Barclays
|
| Announcement date: | Sept. 16
|
| Pricing date: | Sept. 18
|
| Settlement date: | Sept. 22
|
| Stock symbol: | Nasdaq: PETX
|
| Stock price: | $10.07 at close Sept. 17
|
| Market capitalization: | $288.69 million
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
